Sorrento’s proprietary G-MAB technology, invented by Dr. Ji, is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences. This makes it one of the largest fully human antibody libraries in the biopharmaceutical industry. Thus far, Sorrento Therapeutics has successfully identified fully human antibodies against over 100 clinically-relevant high-impact oncogenic targets, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and CCR2.

G-MAB Library

  • Highly successful screening hit rate (100+ clinically relevant targets screened).
  • Very high diversity (2.x x 1016 distinct antibody sequences)
  • Proprietary technology (RNA amplification for library generation)

Manufacturing Capabilities:

  • cGMP facility
  • Fill/finish capabilities
  • Full analytical support

Immuno-Oncology Assets

G-MABS CAR-T ADCs iTAbs Oncolytic Virus